• Real Time Chart Real Time Chart
  • Stock Profile Stock Profile
  • Financials As Reported

    • accession Number 0001370368-22-000010
    • amendment Flag false
    • assets 131,795,000,000
    • auditor Firm Id 1,358
    • auditor Location Basel, Switzerland
    • auditor Name PricewaterhouseCoopers AG
    • cik 1,114,448
    • current Fiscal Year End Date --12-31
    • date Filed 2022-02-02
    • document Annual Report true
    • document Fiscal Period Focus FY
    • document Fiscal Year Focus 2,021
    • document Period End Date 2021-12-31
    • document Transition Report false
    • document Type 20-F
    • entity Address Address Line 1 Lichtstrasse 35
    • entity Address City Or Town Basel
    • entity Address Postal Zip Code 4,056
    • entity Central Index Key 1,114,448
    • entity Current Reporting Status Yes
    • entity Emerging Growth Company false
    • entity File Number 1-15024
    • entity Filer Category Large Accelerated Filer
    • entity Incorporation State Country Code V8
    • entity Interactive Data Current Yes
    • entity Name NOVARTIS AG
    • entity Registrant Name Novartis AG
    • entity Shell Company false
    • entity Voluntary Filers No
    • entity Well Known Seasoned Issuer Yes
    • gross Profit 37,010,000,000
    • icfr Auditor Attestation Flag true
    • interest Expense 811,000,000
    • irs Number 0
    • liabilities 63,973,000,000
    • noncurrent Assets 86,077,000,000
    • period End 1,640,908,800,000
    • period Start 1,609,459,200,000
    • report Link https://www.sec.gov/Archives/edgar/data/1114448/000137036822000010/nvs-20211231_htm.xml
    • research And Development Expense 9,540,000,000
    • selling General And Administrative Expense 14,886,000,000
    • trading Symbol NVS
    • update 1970-01-01
    • id REPORTED_FINANCIALS
    • key NVS
    • subkey 20-F
    • date 2022-02-02
    • updated 2022-05-14
  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

NVS stock fundamentals - financials as reported

Financials As Reported

  • accession Number 0001370368-22-000010
  • amendment Flag false
  • assets 131,795,000,000
  • auditor Firm Id 1,358
  • auditor Location Basel, Switzerland
  • auditor Name PricewaterhouseCoopers AG
  • cik 1,114,448
  • current Fiscal Year End Date --12-31
  • date Filed 2022-02-02
  • document Annual Report true
  • document Fiscal Period Focus FY
  • document Fiscal Year Focus 2,021
  • document Period End Date 2021-12-31
  • document Transition Report false
  • document Type 20-F
  • entity Address Address Line 1 Lichtstrasse 35
  • entity Address City Or Town Basel
  • entity Address Postal Zip Code 4,056
  • entity Central Index Key 1,114,448
  • entity Current Reporting Status Yes
  • entity Emerging Growth Company false
  • entity File Number 1-15024
  • entity Filer Category Large Accelerated Filer
  • entity Incorporation State Country Code V8
  • entity Interactive Data Current Yes
  • entity Name NOVARTIS AG
  • entity Registrant Name Novartis AG
  • entity Shell Company false
  • entity Voluntary Filers No
  • entity Well Known Seasoned Issuer Yes
  • gross Profit 37,010,000,000
  • icfr Auditor Attestation Flag true
  • interest Expense 811,000,000
  • irs Number 0
  • liabilities 63,973,000,000
  • noncurrent Assets 86,077,000,000
  • period End 1,640,908,800,000
  • period Start 1,609,459,200,000
  • report Link https://www.sec.gov/Archives/edgar/data/1114448/000137036822000010/nvs-20211231_htm.xml
  • research And Development Expense 9,540,000,000
  • selling General And Administrative Expense 14,886,000,000
  • trading Symbol NVS
  • update 1970-01-01
  • id REPORTED_FINANCIALS
  • key NVS
  • subkey 20-F
  • date 2022-02-02
  • updated 2022-05-14